Evogene (NASDAQ:EVGN) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a research report released on Sunday morning. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Lake Street Capital dropped their price objective on shares of Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, August 23rd.

Evogene Stock Performance

Shares of EVGN stock opened at $1.88 on Friday. The firm’s 50 day moving average price is $2.54 and its 200-day moving average price is $4.68. Evogene has a one year low of $1.70 and a one year high of $10.40. The firm has a market cap of $10.10 million, a P/E ratio of -0.47 and a beta of 1.43.

Evogene (NASDAQ:EVGN) last issued its quarterly earnings data on Thursday, August 22nd. The biotechnology company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.94). Evogene had a negative return on equity of 72.33% and a negative net margin of 210.26%. The company had revenue of $0.91 million during the quarter.

Institutional Trading of Evogene

A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC purchased a new position in shares of Evogene Ltd. (NASDAQ:EVGN) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is owned by institutional investors.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.